Suppr超能文献

颅底肿瘤碳离子放疗后脑损伤的危险因素。

Risk factors for brain injury after carbon ion radiotherapy for skull base tumors.

作者信息

Koto Masashi, Hasegawa Azusa, Takagi Ryo, Fujikawa Akira, Morikawa Takamichi, Kishimoto Riwa, Jingu Keiichi, Tsujii Hirohiko, Kamada Tadashi

机构信息

Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba, Japan.

Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba, Japan.

出版信息

Radiother Oncol. 2014 Apr;111(1):25-9. doi: 10.1016/j.radonc.2013.11.005. Epub 2013 Dec 11.

Abstract

BACKGROUND AND PURPOSE

This study aimed to determine the risk factors for radiation-induced brain injury (RIBI) after carbon ion radiotherapy (CIRT) for treating skull base tumors.

MATERIALS AND METHODS

Between April 1997 and January 2009, CIRT at a total dose of 48.0-60.8Gy equivalent (GyE) was administered in 16 fractions to 47 patients with skull base tumors. Of these patients, 39 who were followed up with magnetic resonance imaging (MRI) for more than 24months were analyzed. RIBI was assessed according to the MRI findings based on the Late Effects of Normal Tissue-Subjective, Objective, Management, Analytic criteria; clinical symptoms were assessed according to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer tables. The correlations of clinical and dosimetric parameters with incidence of ⩾grade 2 RIBI were retrospectively analyzed.

RESULTS

The median follow-up period was 67months. The 5-year actuarial likelihoods of ⩾grade 2 RIBI and ⩾grade 2 clinical symptoms were 24.5% and 7.0%, respectively. Multivariate analysis demonstrated that the brain volume receiving more than 50GyE (V50) was a significant risk factor for the development of ⩾grade 2 RIBI (p=0.004).

CONCLUSION

V50 was a significant risk factor for ⩾grade 2 RIBI after CIRT using a 16-fraction regimen.

摘要

背景与目的

本研究旨在确定碳离子放疗(CIRT)治疗颅底肿瘤后放射性脑损伤(RIBI)的危险因素。

材料与方法

1997年4月至2009年1月期间,对47例颅底肿瘤患者进行了总剂量为48.0 - 60.8Gy等效剂量(GyE)的CIRT,分16次给予。其中,对39例接受磁共振成像(MRI)随访超过24个月的患者进行了分析。根据基于正常组织晚期效应-主观、客观、管理、分析标准的MRI结果评估RIBI;根据放射肿瘤学组/欧洲癌症研究与治疗组织的表格评估临床症状。回顾性分析临床和剂量学参数与≥2级RIBI发生率的相关性。

结果

中位随访期为67个月。≥2级RIBI和≥2级临床症状的5年精算发生率分别为24.5%和7.0%。多因素分析表明,接受超过50GyE的脑体积(V50)是发生≥2级RIBI的显著危险因素(p = 0.004)。

结论

使用16分次方案进行CIRT后,V50是≥2级RIBI的显著危险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验